EICHORCondition: Parkinson Disease (PD) · Sponsor: Yousheng Xiao
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This observational, multicenter, case-control study aims to evaluate the efficacy and safety of Entacapone combined with Madopar (levodopa/benserazide) in the treatment of early-stage Parkinson's disease (PD) among Chinese patients. The study will enroll patients diagnosed with PD according to the MDS criteria, aged 18-80, with modified Hoehn-Yahr stages 1-2.5, and who have not previously used Entacapone. Participants will be assigned to two groups based on their prior treatment history: the LBE group (levodopa/benserazide/entacapone) or the LB group (levodopa/benserazide only), according to their actual clinical treatment plan. The study will observe patients over a 24-week period, evaluating changes in motor symptoms using the MDS-UPDRS Part III score as the primary endpoint. Secondary outcomes include assessments of daily living abilities, motor complications, quality of life (PDQ-39), cognitive function (MMSE), global impression (CGI), and safety profiles, including adverse event reporting. This study does not involve any interventional treatment changes; all therapeutic decisions remain at the discretion of the treating physicians. The findings are expected to provide real-world evidence regarding the potential benefits and safety of adding Entacapone to Madopar in the management of early PD.
This description comes directly from the study's public registry record.
Yousheng Xiao, PhD · +86-15177196935 · xys135@126.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: Age between 18 and 80 years; Diagnosed with Parkinson's Disease based on the MDS criteria, confirmed by a movement disorder neurologist; Modified Hoehn and Yahr stage between 1 and 2.5; No prior use of entacapone; MMSE score ≥ 26; BDI (Beck Depression Inventory) score \< 15; Either: Has never used levodopa before, or Has been on a stable dose of levodopa (300-600 mg/day) for at least 1 month prior to enrollment; Stable doses of amantadine, anticholinergics, dopamine agonists, selegiline, or rasagiline are allowed if maintained for at least 30 days prior to and during the study; Willing and able to give informed consent and comply with study procedures, with caregiver support if needed. Exclusion Criteria: Previous use of entacapone or tolcapone for more than 30 days, or within 4 weeks before baseline; Use of dopamine agonists within 4 weeks before baseline; BDI score ≥ 15; MMSE score \< 26; Unstable levodopa dosage; History of dyskinesia; Diagnosis of atypical or secondary parkinsonism, or history of PD-related neurosurgery; Clinically significant medical conditions within the past 5 years that could interfere with study participation; Use of medications known to induce parkinsonism; Participation in other investigational drug trials within 30 days before baseline.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| The First Affiliated Hospital of Guangxi Medical University | Nanning, Guanxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06928519